放射治疗高能光子束吸收剂量不同测定规程的比较

目的 :介绍美国医学物理学家协会 (AAPM)最新颁布的高能光子束吸收剂量的测定规程。　方法 :以我院实际使用的剂量仪和电离室按照第 3代规程中推荐的方法测定医用直线加速器 6 MV高能光子束的吸收剂量。　结果 :新规程与第 1代规程比较的差异在 3%左右 ,与第 2代规程相比 ,差异 <1%。　结论 :新一代规程理论严谨 ,表达简明 ,具有更好的精度和最大程度上的应用方便性     

不同照射剂量及照后培养不同时间小鼠骨髓基质细胞损伤的变化

目的 :研究γ射线照射剂量及照射后培养时间对体外培养的骨髓基质细胞 (BMSC)损伤的影响。方法 :体外培养的BMSC随机分为正常组和不同剂量照射组 ,利用流式细胞仪 (FCM)、HE染色等技术观察处理后BMSC凋亡率和坏死率的变化。结果 :照射剂量从 0增至 5 0Gy时 ,凋亡率和坏死率随照后培养时间的延长其增加的幅度较小 ,当照射剂量从 5 0Gy增至 70Gy时 ,其增加幅度较大 ;当剂量大于 70Gy时 ,BMSC的损伤主要表现为坏死率的相对增高。结论 :BMSC的凋亡和坏死与照射剂量和照后培养时间有关 ,且表现出一定的规律性     

真空紫外辐照对加成型硅橡胶光学性能的影响

考察了加成型硅橡胶在真空环境中经1000ESH紫外辐照后的性能变化。结果表明,辐照后材料均出现发黄的现象,光学透过率大幅度 下降,同时加入硅酸钾包覆后制备的热控涂层反射率下降。经原位测试与离位测试,发现加成型硅橡胶在两种不同条件下测得的结果差异较小,而在有机硅橡胶中加入ZnO后原位与离位测试结果则差异明显,表现出明显的漂白作用。     

肉苁蓉总苷对~(60)Coγ射线损伤小鼠免疫功能的防护作用

目的　研究肉苁蓉总苷 (GCs)对 6 0 Co损伤小鼠免疫功能及 30 d存活率的影响。方法　小鼠在不同剂量6 0 Coγ射线照射前后 ,均服以 GCs,观察辐射及 GCs对其免疫功能的改变。结果　 6 0 Co照射剂量为 2 ,4及 7Gy时 ,可造成小鼠体液免疫、细胞免疫功能和非特异性免疫功能及 30 d存活率下降 (P<0 .0 5或 P<0 .0 1) ;GCs(31.2 5 ,6 2 .5 ,12 5 m g/ kg)组可促进上述各指标的恢复 ,对 6 0 Co损伤小鼠的抗体产生、外周血 T淋巴细胞数目、迟发型超敏反应、腹腔巨噬细胞的吞噬功能均有明显保护作用 (P<0 .0 1或 P<0 .0 5 ) ;且能提高受照小鼠的脾指数、胸腺指数及 30 d存活率 (P<0 .0 1或 P<0 .0 5 )。结论　 GCs对辐射损伤小鼠的免疫功能具有较强防护作用     

电磁辐射对小鼠神经系统超微结构影向的分析

目的探讨移动电话的电磁辐射对生物体的影响.方法用大众常用移动电话作为辐射源,工作频率为900MHz,功率密度为1190μW/cm2,在一定范围对小鼠辐射2h/d,30d后把小鼠断颈处死,取出大脑皮层、海马和小脑进行电镜观察分析.结果电镜所见,处理组与对照组小鼠的神经系统的细胞超微结构未见明显异常.结论一定时间内,移动电话的电磁辐射,对小鼠神经系统的细胞超微结构并没有明显影响.     

Principles of cancer treatment by radiotherapy

Radiotherapy (or radiation therapy) uses ionizing radiation to selectively kill cancer cells, especially for solid tumours. Like surgery, it is meant to be a ‘local’ treatment, although its beneficial systemic effects are being discovered. It is most commonly used in addition to surgery (adjuvant, e.g. breast), but its role in the neoadjuvant setting in combination with chemotherapy for some cancers (e.g. rectum) is also established. In early stages of cancer, it can be the definitive treatment, avoiding surgery and enabling organ preservation (e.g. larynx), while in late stages, it can provide excellent palliation (e.g. bone metastasis). Radiotherapy can be delivered at various energy levels (kiloVolts, megaVolts), with various subatomic particles (e.g. electrons, protons, and high-energy electromagnetic radiation). The traditional bulky equipment (e.g. linear accelerator) needs to be housed in an underground bunker and uses complex imaging to improve precision and avoid radiation to normal tissues. Fractionated regimens spanning several days reduce individual doses. Modern techniques using mobile devices (e.g. TARGIT-IORT) can deliver radiotherapy during surgery with the highest precision and immediacy.     

Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer

BackgroundThe phase 3 NCT00793962 trial demonstrated that postmastectomy hypofractionated radiation therapy (HFRT) was noninferior to conventional fractionated radiation therapy (CFRT) in patients with high-risk breast cancer. This study assessed the cost-effectiveness of postmastectomy HFRT vs CFRT based on the NCT00793962 trial.MethodsA Markov model was adopted to synthesize the medical costs and health benefits of patients with high-risk breast cancer based on data from the NCT00793962 trial. Main outcomes were discounted lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). We employed a time-dependent horizon from Chinese, French and USA payer perspectives. Model robustness was evaluated with one-way and probabilistic sensitivity analyses.ResultsPatients receiving CFRT versus HFRT gained an incremental 0.0163 QALYs, 0.0118 QALYs and 0.0028 QALYs; meanwhile an incremental cost of $2351.92, $4978.34 and $8812.70 from Chinese, French and USA payer perspectives, respectively. Thus CFRT versus HFRT yielded an ICER of $144,281.47, $420,636.10 and $3,187,955.76 per QALY from Chinese, French and USA payer perspectives, respectively. HFRT could maintain a trend of >50% probabilities of cost-effectiveness below a willingness-to-pay (WTP) of $178,882.00 in China, while HFRT was dominant relative to CFRT, regardless of the WTP values in France and the USA. Sensitivity analyses indicated that the ICERs were most sensitive to the parameters of overall survival after radiotherapy.ConclusionsPostmastectomy HFRT could be used as a cost-effective substitute for CFRT in patients with high-risk breast cancer and should be considered in appropriately selected patients.     

基于“病-药-量”探讨《中华医典》含竹沥中药方剂相应规律的数据挖掘

目的 分析《中华医典》中含有竹沥中药方剂“病-药-量”的相应规律,为竹沥的临床诊疗应用及深入研发提供参考。方法 收集整理《中华医典》中含有竹沥的中药方剂,录入Excel 2016构建临证方药数据库,对其病症、证型、药物使用频次、功效类别、性味归经、剂型及用量等进行统计分析,运用SPSS Statistics 22.0、IBM SPSS Modeler 18.0软件进行关联规则、聚类分析等数据挖掘。结果 共收集含竹沥方剂349首,主治病证分类共99种,其中高频病证（≥20次）主要为“中风”“痰饮”“咳嗽”,治疗“中风”证型以风痰瘀阻为主,“痰饮”以饮停胃肠为主,“咳嗽”以痰热郁肺为主;组方中使用频次≥50次的药物有19味,使用频次较高的有生姜、甘草、茯苓、陈皮等,药物功效种类以化痰止咳平喘药、补虚药、清热药为主;药性使用频次最高的为寒性药,其次为温性药,药味多选用甘、苦、辛味,药物归经以脾、胃、心经为主;高频病症剂型及药物用量分析显示,治疗“中风”时,剂型多为汤剂,竹沥用量多为100 mL,核心药物配伍重用防风以祛风化痰,改善脑络痹阻;治疗“痰饮”时,剂型多为丸剂,竹沥用量为200 mL...